Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Vaccinations With ALVAC-CEA and Vaccinia-CEA +/- IL-2 and GM-CSF in CEA Expressing Tumors
NCT00003125Phase 2Completed
- Sponsor
- Georgetown University
- Start
- Jan 1998
- Primary completion
- Nov 2004
- Modality
- Gene Editing, Vaccines & Immunotherapeutics, Viral Vectors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ALVAC-CEA and rV-CEA in Neoplasm (4 arms), sponsored by Georgetown University. Primary endpoint: Safety and Toxicity up to 2 years. Started Jan 1998; status: completed.
02
Drugs
ALVAC-CEArV-CEA
03
Conditions
Neoplasm
Beyond the preview
Go deeper on NCT00003125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003125.